NEW YORK (GenomeWeb) – Alnylam Pharmaceuticals this week released early Phase I data on its subcutaneously administered hemophilia therapy ALN-AT3, which showed the drug could durably suppress its target by as much as 57 percent at low microgram per kilogram doses.

Notably, ALN-AT3 is Alnylam's first clinical candidate to feature an optimized version of the company's GalNAc conjugate delivery technology, dubbed enhanced stabilization chemistry, which is expected to replace standard GalNAc conjugates in future Alnylam programs.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.